eganelisib + pembrolizumab

This drug entry refers to the combination therapy of eganelisib (IPI-549) and pembrolizumab (Keytruda). Eganelisib is an orally administered, small-molecule inhibitor of phosphoinositide 3-kinase gamma (PI3K-gamma), developed by Infinity Pharmaceuticals. PI3K-gamma is highly expressed in myeloid cells within the tumor microenvironment; its inhibition is designed to reprogram pro-tumor macrophages into an anti-tumor state, thereby overcoming resistance to immune checkpoint inhibitors. Pembrolizumab is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, an immune checkpoint. The combination is being investigated in several solid tumors, including non-small cell lung cancer (NSCLC), to enhance the efficacy of PD-1 blockade by modulating the immunosuppressive myeloid environment. Note: While the provided context mentions a Phase 2 trial of IPI-504 (retaspimycin) and docetaxel (the RING trial), that study is historically distinct and refers to a discontinued Hsp90 inhibitor; the name 'Keytruda-Infinity' specifically identifies the current eganelisib/pembrolizumab development program.

Brand names

Keytruda

Other names

pembrolizumab + eganelisibIPI-549 and pembrolizumabIPI549 and pembrolizumabIPI 549 and pembrolizumab